Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
- None.
- None.
Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025
WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this , or visit 鈥溾�� in the Investors section of the Company鈥檚 website at . A replay of the webcast and copy of the presentation will be available following the event.听
About STAT6 and KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to provide the convenience of an oral medicine with the potential for biologics-like activity and in doing so reach broader patient populations compared to injectable biologics or other standards of care. In preclinical studies, KT-621 demonstrated dupilumab-like activity in several听in vitro听补苍诲听in vivo听models and was safe and well tolerated. KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and adults, suffering from Th2 diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), bullous pemphigoid (BP), and chronic spontaneous urticaria (CSU), among others.
KT-621 is currently being evaluated in a Phase 1b trial (BroADen) in atopic dermatitis patients, with data from the study expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.
About Kymera Therapeutics听
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients鈥� lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston鈥檚 top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on or .听
Availability of Other Information About Kymera Therapeutics听
For more information, please visit the Kymera website at or follow Kymera on and ). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on and . The information that Kymera posts on its website or on or could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera鈥檚 website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.听
Investor and Media Contact:听
Justine Koenigsberg
Vice President, Investor Relations
857-285-5300听
FAQ
When will Kymera Therapeutics (KYMR) announce KT-621 Phase 1 trial results?
What is the purpose of Kymera's KT-621 Phase 1 trial?
How can investors access Kymera's KT-621 Phase 1 results presentation?
What type of medicines is Kymera Therapeutics (KYMR) developing?
